Ibrutinib for untreated mantle cell lymphoma [ID1221]
Discontinued
Reference number: GID-TA10185
As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ibrutinib for untreated mantle cell lymphoma.
Following an update from the company, the timelines for this appraisal are to be confirmed in order to align with latest regulatory expectations.
Therefore, NICE will continue to monitor development and will update interested parties as and when the situation changes.